Genelux Corporation (NASDAQ:GNLX) Given Average Recommendation of "Buy" by Analysts

Key Points

• Genelux Corporation (NASDAQ:GNLX) has received an overall average rating of "Buy" from analysts, with four firms recommending a buy and one a strong buy.
• The current one-year target price for Genelux stock is $17.75, despite its recent trading price of $3.36.
• Institutional investors hold 37.33% of Genelux shares, indicating significant interest from large financial firms in the company.

Shares of Genelux Corporation (NASDAQ:GNLX - Get Free Report) have earned an average recommendation of "Buy" from the five analysts that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $17.75.

Several analysts have recently weighed in on the stock. Benchmark lowered their price objective on shares of Genelux from $25.00 to $23.00 and set a "speculative buy" rating on the stock in a research report on Thursday, May 8th. HC Wainwright reissued a "buy" rating on shares of Genelux in a report on Wednesday, July 23rd. Finally, Wall Street Zen raised shares of Genelux from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th.

Genelux Stock Performance

NASDAQ GNLX traded up $0.34 on Thursday, hitting $3.78. The stock had a trading volume of 142,823 shares, compared to its average volume of 87,582. Genelux has a 52-week low of $1.95 and a 52-week high of $5.89. The company has a market capitalization of $142.78 million, a price-to-earnings ratio of -4.40 and a beta of -0.32. The firm has a 50-day moving average of $3.26 and a 200-day moving average of $3.23.

Genelux (NASDAQ:GNLX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02. As a group, research analysts anticipate that Genelux will post -0.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genelux

Several hedge funds have recently bought and sold shares of GNLX. LPL Financial LLC raised its holdings in Genelux by 72.3% in the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company's stock worth $222,000 after buying an additional 39,516 shares during the last quarter. Woodward Diversified Capital LLC raised its holdings in Genelux by 15.2% in the first quarter. Woodward Diversified Capital LLC now owns 1,461,113 shares of the company's stock worth $3,945,000 after buying an additional 192,808 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Genelux in the fourth quarter worth about $41,000. Liberty Wealth Management LLC purchased a new position in Genelux in the first quarter worth about $45,000. Finally, Marshall Wace LLP raised its holdings in Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock worth $368,000 after buying an additional 52,958 shares during the last quarter. Institutional investors own 37.33% of the company's stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.